NCT00492258已完成3 期
SORCE: A Phase III Randomised Double-Blind Study Comparing Sorafenib With Placebo in Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,656
- 试验地点
- 39
- 主要终点
- Disease-free survival
研究概览
简要总结
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sorafenib after surgery may kill any tumor cells that remain after surgery. It is not yet known whether sorafenib is more effective than a placebo in treating kidney cancer.
PURPOSE: This randomized phase III trial is studying sorafenib to see how well it works compared with a placebo in treating patients at risk of relapse after undergoing surgery to remove kidney cancer.
详细描述
OBJECTIVES:
- Compare disease-free survival of patients with resected primary renal cell carcinoma at high- or intermediate-risk of relapse treated with a placebo for 3 years vs a placebo for 2 years and sorafenib tosylate for 1 year vs sorafenib tosylate for 3 years.
OUTLINE: This is a randomized, placebo-controlled, double-blind, open-label, multicenter study. Patients are randomized to 1 of 3 treatment arms.
- Arm I: Patients receive oral placebo twice daily for 3 years in the absence of disease progression or unacceptable toxicity.
- Arm II: Patients receive oral sorafenib tosylate twice daily for 1 year and oral placebo twice daily for 2 years in the absence of disease progression or unacceptable toxicity.
- Arm III: Patients receive oral sorafenib tosylate twice daily for 3 years in the absence of disease progression or unacceptable toxicity.
Patients in arms I and II with progressive disease may cross over and receive treatment in arm III.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically confirmed renal cell carcinoma (RCC)
- •Clear cell or non-clear cell tumors allowed
- •Intermediate- or high-risk disease (Leibovich score 3 to 11)
- •Must have undergone surgery for RCC at least 4 weeks but no more than 3 months prior to study entry
- •No evidence of residual macroscopic disease on post-operative CT scan after resection of RCC
- •PATIENT CHARACTERISTICS:
- •WHO performance status 0-1
- •WBC > 3,400/mm³
- •Platelet count > 99,000/mm³
- •Creatinine < 2.5 times upper limit of normal (ULN)
- •Liver function tests < 1.5 times ULN
- •Serum amylase < 1.5 times ULN
- •PT/INR < 1.5 times ULN
- •PTT < 1.5 times ULN
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception during and for 9 months after completion of study treatment
- •No cardiovascular conditions, including any of the following:
- •Cardiac arrhythmias requiring anti-arrhythmic medication
- •Beta-blockers and digoxin allowed
- •Symptomatic coronary artery disease or ischemia
- •Myocardial infarction within the past 6 months
- •NYHA class II-IV congestive heart failure
- •No active clinically serious bacterial or fungal infection
- •No known history of HIV infection
- •No chronic hepatitis B or C
- •No other prior malignancy except carcinoma in situ of the cervix or adequately treated basal cell carcinoma
- •No uncontrolled hypertension
- •PRIOR CONCURRENT THERAPY:
- •See Disease Characteristics
- •No prior treatment for RCC other than nephrectomy
- •More than 30 days since prior and no other concurrent investigational therapy
- •No concurrent medications that have adverse interactions with sorafenib tosylate including, but not limited to, any of the following:
- •Grapefruit juice
- •Ritonavir
- •Ketoconazole
- •Itraconazole
- •Hypericum perforatum (St John's wort)
- •No concurrent bone marrow transplant or stem cell rescue
- •No other concurrent drug that targets angiogenesis, especially VEGF or VEGF receptors (e.g., bevacizumab)
- •No other concurrent drug that targets Ras-pathway or EGFR
- •No other concurrent anticancer therapy (chemotherapy, immunotherapy, signal transduction inhibition, or hormonal therapy)
- •Concurrent non-conventional therapies (e.g., herbs or acupuncture) and vitamin or mineral supplements allowed
- •Concurrent bisphosphonates for prophylaxis of osteoporosis allowed
排除标准
- 未提供
结局指标
主要结局
Disease-free survival
次要结局
- Metastasis-free survival
- Disease-specific survival time
- Overall survival
- Cost effectiveness
- Toxicity
研究者
研究点 (39)
Loading locations...
相似试验
已完成
2 期
Sorafenib in Treating Patients With Angiosarcoma That is Locally Advanced, Metastatic, or Unable to Be Removed by SurgerySarcomaNCT00874874Centre Oscar Lambret88
已完成
2 期
Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone TherapyProstate CancerNCT00589420Abramson Cancer Center at Penn Medicine18
终止
2 期
Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung CancerLung CancerNCT00754923Ohio State University Comprehensive Cancer Center11
撤回
1 期
Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung CancerLung CancerNCT00547443University of Texas Southwestern Medical Center
终止
2 期
Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor TherapyBreast CancerNCT00722072OHSU Knight Cancer Institute12